Keros Therapeutics Inc (KROS)

$18.01 +0.18 (1.01%)
Market Cap 557.53M
Revenue (ttm) 3.55M
Net Income (ttm) -187.35M
EPS (ttm) N/A
PE Ratio 12.19
Forward PE N/A
Profit Margin -5,277.47%
Debt to Equity Ratio 0.00
Volume 119,472
Avg Vol 715,682
Day's Range N/A - N/A
Shares Out 30.47M
Stochastic %K 1%
Beta 0.89
Analysts Sell
Price Target $23.50

Company Profile

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in pat...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 314 6297
Address:
1050 Waltham Street, Suite 302, Lexington, United States
ZacksResearch
ZacksResearch Jan. 27 at 8:25 PM
$KROS vs. $DYN: Why KROS is the better biotech bet? 🚀 Keros Therapeutics is showing strong potential with a Zacks Rank #1 (Strong Buy), a 63.9% surge in share price over the past year, and a cheaper valuation at 0.81x book value. Its lead DMD candidate, KER-065, is making significant progress with promising phase I results in healthy volunteers and FDA orphan drug designation, with a phase II trial planned for DMD patients. Discover why KROS stands out in the biotech sector 👉 https://www.zacks.com/stock/news/2823320/keros-therapeutics-vs-dyne-which-dmd-biotech-has-more-upside?cid=sm-stocktwits-2-2823320-body-30571&ADID=SYND_STOCKTWITS_TWEET_2_2823320_BODY_30571
0 · Reply
ZacksResearch
ZacksResearch Jan. 27 at 7:25 PM
$KROS vs. $DYN — which DMD biotech offers the better upside from here? 🧬 Keros Therapeutics is advancing KER-065 toward DMD trials, cutting costs, and extending its cash runway, while investors stack that progress against Dyne’s deeper pipeline. See the full head-to-head here 👉 https://www.zacks.com/stock/news/2823320/keros-therapeutics-vs-dyne-which-dmd-biotech-has-more-upside?cid=sm-stocktwits-2-2823320-teaser-30570&ADID=SYND_STOCKTWITS_TWEET_2_2823320_TEASER_30570
0 · Reply
ZacksResearch
ZacksResearch Jan. 16 at 2:13 PM
$KROS up 77.3% over the past year — is there more upside ahead? 🚀 🧪 Focused on KER-065 with phase II for DMD starting Q1 2026 📈 Shares trading at just 0.83x tangible book value vs. industry average 3.61x 💰 2025 EPS estimate up to $2.25, and KROS holds a Zacks Rank #1 (Strong Buy) See what makes KROS a compelling prospect here 👉 https://www.zacks.com/stock/news/2818727/will-kros-stocks-restructuring-efforts-reap-rewards-for-investors?cid=sm-stocktwits-2-2818727-body-29222&ADID=SYND_STOCKTWITS_TWEET_2_2818727_BODY_29222
0 · Reply
MacGruber99
MacGruber99 Jan. 16 at 1:43 PM
$KROS They are laying the foundations for a long term revenue generating platform. Elritercept is moving forward on schedule with continued enrollment for pivotal trials by Takeda, and the strategy for KER-065 in DMD and ALS show confidence in the neuromuscular hypothesis and focus. Muscle mass is expected to improve in those disorders with KER-065, but the question will be to what degree and with how much impact on function. It is an important approach and question, and this is currently the best in class tool to test this concept. 2026 will be an important year for KROS.
0 · Reply
ZacksResearch
ZacksResearch Jan. 16 at 1:13 PM
Can $KROS’ reset finally unlock value — or is this a high-risk pivot? ⚠️ Keros Therapeutics is sharpening its focus on KER-065 for DMD, cutting staff by 45%, shelving cibotercept, and planning a phase II trial in Q1 2026 — while extending its cash runway into 2028. See if this restructuring can pay off for investors 👉 https://www.zacks.com/stock/news/2818727/will-kros-stocks-restructuring-efforts-reap-rewards-for-investors?cid=sm-stocktwits-2-2818727-teaser-29220&ADID=SYND_STOCKTWITS_TWEET_2_2818727_TEASER_29220
1 · Reply
ZacksResearch
ZacksResearch Jan. 15 at 4:34 PM
$KROS skyrocketed 85.6% in a year — what's fueling the rally? 🚀 📈 Strategic review + pipeline progress = investor enthusiasm 💊 Key developments: KER-065 for DMD and elritercept licensing with Takeda 💰 Valuation: Trading at 0.85x tangible book value based on the price/book ratio, well below industry average With a Zacks Rank #1, find out if KROS is a hidden gem 👉 https://www.zacks.com/stock/news/2817957/kros-stock-surges-856-in-a-year-more-upside-potential-in-2026?cid=sm-stocktwits-2-2817957-body-29113&ADID=SYND_STOCKTWITS_TWEET_2_2817957_BODY_29113
0 · Reply
ZacksResearch
ZacksResearch Jan. 15 at 3:34 PM
$KROS up 85.6% in a year — and bulls are already eyeing what’s next. 🔥 The move is being driven by a strategic review and pipeline progress led by KER-065 and elritercept, reigniting investor enthusiasm and putting 2026 upside back in focus. See what could keep momentum going into 2026 👉 https://www.zacks.com/stock/news/2817957/kros-stock-surges-856-in-a-year-more-upside-potential-in-2026?cid=sm-stocktwits-2-2817957-teaser-29110&ADID=SYND_STOCKTWITS_TWEET_2_2817957_TEASER_29110
0 · Reply
sprmn
sprmn Jan. 10 at 1:04 AM
$KROS Takeda is presenting next week. Another milestone has been achieved. 🚀🚀🚀🔥🔥🔥
0 · Reply
MacGruber99
MacGruber99 Jan. 9 at 9:55 PM
$KROS After hours: Corporate update SEC 8-K. Progress with elritercept, and plan to apply KER-065 in ALS as well as DMD based on encouraging findings of other muscle protective strategies in preserving function in ALS, and preclinical evidence of protective effects of KER-065 in mouse ALS models with improvement in neuromuscular junction structure/function and motor strength. https://www.sec.gov/Archives/edgar/data/1664710/000166471026000003/keros-corporatepresentat.htm
0 · Reply
MacGruber99
MacGruber99 Jan. 9 at 3:19 AM
$KROS tutes be loading up and unloading all the time. float is so small that these events will move the needle.
0 · Reply
Latest News on KROS
Keros Therapeutics Announces Final Results of Tender Offer

Nov 20, 2025, 4:01 PM EST - 2 months ago

Keros Therapeutics Announces Final Results of Tender Offer

Keros Therapeutics Announces Preliminary Results of Tender Offer

Nov 19, 2025, 6:00 AM EST - 2 months ago

Keros Therapeutics Announces Preliminary Results of Tender Offer

Keros Therapeutics Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:01 PM EST - 3 months ago

Keros Therapeutics Reports Third Quarter 2025 Financial Results

Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares

Oct 20, 2025, 6:00 AM EDT - 3 months ago

Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

Oct 15, 2025, 6:30 AM EDT - 3 months ago

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting

Sep 8, 2025, 8:00 AM EDT - 5 months ago

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

Aug 28, 2025, 4:01 PM EDT - 5 months ago

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

Aug 21, 2025, 8:30 AM EDT - 5 months ago

ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

Aug 20, 2025, 9:48 AM EDT - 5 months ago

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Aug 6, 2025, 4:15 PM EDT - 6 months ago

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Keros Therapeutics Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 4:01 PM EDT - 6 months ago

Keros Therapeutics Reports Second Quarter 2025 Financial Results

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

Jul 17, 2025, 8:00 AM EDT - 7 months ago

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

Jun 9, 2025, 3:12 PM EDT - 8 months ago

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

Keros Announces Return of $375 Million in Excess Capital to Stockholders

Jun 9, 2025, 6:55 AM EDT - 8 months ago

Keros Announces Return of $375 Million in Excess Capital to Stockholders

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

Jun 6, 2025, 4:01 PM EDT - 8 months ago

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

May 29, 2025, 6:55 AM EDT - 8 months ago

Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros' Director Nominees

May 27, 2025, 1:45 PM EDT - 8 months ago

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros' Director Nominees

ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth

May 21, 2025, 8:00 AM EDT - 9 months ago

ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth

ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth

May 12, 2025, 12:11 PM EDT - 9 months ago

ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth

Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference

May 12, 2025, 8:00 AM EDT - 9 months ago

Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference

Keros Reinforces Commitment to Maximizing Stockholder Value

May 8, 2025, 5:31 PM EDT - 9 months ago

Keros Reinforces Commitment to Maximizing Stockholder Value

ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

May 8, 2025, 2:10 PM EDT - 9 months ago

ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

May 6, 2025, 4:01 PM EDT - 9 months ago

Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan

Apr 10, 2025, 1:51 PM EDT - 10 months ago

Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan

Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump

Apr 10, 2025, 12:12 PM EDT - 10 months ago

Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump

Keros Therapeutics adopts 'poison pill' plan

Apr 10, 2025, 6:10 AM EDT - 10 months ago

Keros Therapeutics adopts 'poison pill' plan

Keros Therapeutics Announces Review of Strategic Alternatives

Apr 10, 2025, 6:00 AM EDT - 10 months ago

Keros Therapeutics Announces Review of Strategic Alternatives

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

Mar 31, 2025, 6:00 AM EDT - 10 months ago

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 4:01 PM EST - 1 year ago

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

Feb 19, 2025, 10:41 AM EST - 1 year ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

ARWR AZN BHVN LLY NVO REGN SRRK

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation

Jan 31, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 30, 2025, 10:00 AM EST - 1 year ago

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 8:00 AM EST - 1 year ago

Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation

Jan 29, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Connect

Jan 28, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation

Jan 27, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation

Jan 26, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 24, 2025, 10:00 AM EST - 1 year ago

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect

Jan 23, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect

ZacksResearch
ZacksResearch Jan. 27 at 8:25 PM
$KROS vs. $DYN: Why KROS is the better biotech bet? 🚀 Keros Therapeutics is showing strong potential with a Zacks Rank #1 (Strong Buy), a 63.9% surge in share price over the past year, and a cheaper valuation at 0.81x book value. Its lead DMD candidate, KER-065, is making significant progress with promising phase I results in healthy volunteers and FDA orphan drug designation, with a phase II trial planned for DMD patients. Discover why KROS stands out in the biotech sector 👉 https://www.zacks.com/stock/news/2823320/keros-therapeutics-vs-dyne-which-dmd-biotech-has-more-upside?cid=sm-stocktwits-2-2823320-body-30571&ADID=SYND_STOCKTWITS_TWEET_2_2823320_BODY_30571
0 · Reply
ZacksResearch
ZacksResearch Jan. 27 at 7:25 PM
$KROS vs. $DYN — which DMD biotech offers the better upside from here? 🧬 Keros Therapeutics is advancing KER-065 toward DMD trials, cutting costs, and extending its cash runway, while investors stack that progress against Dyne’s deeper pipeline. See the full head-to-head here 👉 https://www.zacks.com/stock/news/2823320/keros-therapeutics-vs-dyne-which-dmd-biotech-has-more-upside?cid=sm-stocktwits-2-2823320-teaser-30570&ADID=SYND_STOCKTWITS_TWEET_2_2823320_TEASER_30570
0 · Reply
ZacksResearch
ZacksResearch Jan. 16 at 2:13 PM
$KROS up 77.3% over the past year — is there more upside ahead? 🚀 🧪 Focused on KER-065 with phase II for DMD starting Q1 2026 📈 Shares trading at just 0.83x tangible book value vs. industry average 3.61x 💰 2025 EPS estimate up to $2.25, and KROS holds a Zacks Rank #1 (Strong Buy) See what makes KROS a compelling prospect here 👉 https://www.zacks.com/stock/news/2818727/will-kros-stocks-restructuring-efforts-reap-rewards-for-investors?cid=sm-stocktwits-2-2818727-body-29222&ADID=SYND_STOCKTWITS_TWEET_2_2818727_BODY_29222
0 · Reply
MacGruber99
MacGruber99 Jan. 16 at 1:43 PM
$KROS They are laying the foundations for a long term revenue generating platform. Elritercept is moving forward on schedule with continued enrollment for pivotal trials by Takeda, and the strategy for KER-065 in DMD and ALS show confidence in the neuromuscular hypothesis and focus. Muscle mass is expected to improve in those disorders with KER-065, but the question will be to what degree and with how much impact on function. It is an important approach and question, and this is currently the best in class tool to test this concept. 2026 will be an important year for KROS.
0 · Reply
ZacksResearch
ZacksResearch Jan. 16 at 1:13 PM
Can $KROS’ reset finally unlock value — or is this a high-risk pivot? ⚠️ Keros Therapeutics is sharpening its focus on KER-065 for DMD, cutting staff by 45%, shelving cibotercept, and planning a phase II trial in Q1 2026 — while extending its cash runway into 2028. See if this restructuring can pay off for investors 👉 https://www.zacks.com/stock/news/2818727/will-kros-stocks-restructuring-efforts-reap-rewards-for-investors?cid=sm-stocktwits-2-2818727-teaser-29220&ADID=SYND_STOCKTWITS_TWEET_2_2818727_TEASER_29220
1 · Reply
ZacksResearch
ZacksResearch Jan. 15 at 4:34 PM
$KROS skyrocketed 85.6% in a year — what's fueling the rally? 🚀 📈 Strategic review + pipeline progress = investor enthusiasm 💊 Key developments: KER-065 for DMD and elritercept licensing with Takeda 💰 Valuation: Trading at 0.85x tangible book value based on the price/book ratio, well below industry average With a Zacks Rank #1, find out if KROS is a hidden gem 👉 https://www.zacks.com/stock/news/2817957/kros-stock-surges-856-in-a-year-more-upside-potential-in-2026?cid=sm-stocktwits-2-2817957-body-29113&ADID=SYND_STOCKTWITS_TWEET_2_2817957_BODY_29113
0 · Reply
ZacksResearch
ZacksResearch Jan. 15 at 3:34 PM
$KROS up 85.6% in a year — and bulls are already eyeing what’s next. 🔥 The move is being driven by a strategic review and pipeline progress led by KER-065 and elritercept, reigniting investor enthusiasm and putting 2026 upside back in focus. See what could keep momentum going into 2026 👉 https://www.zacks.com/stock/news/2817957/kros-stock-surges-856-in-a-year-more-upside-potential-in-2026?cid=sm-stocktwits-2-2817957-teaser-29110&ADID=SYND_STOCKTWITS_TWEET_2_2817957_TEASER_29110
0 · Reply
sprmn
sprmn Jan. 10 at 1:04 AM
$KROS Takeda is presenting next week. Another milestone has been achieved. 🚀🚀🚀🔥🔥🔥
0 · Reply
MacGruber99
MacGruber99 Jan. 9 at 9:55 PM
$KROS After hours: Corporate update SEC 8-K. Progress with elritercept, and plan to apply KER-065 in ALS as well as DMD based on encouraging findings of other muscle protective strategies in preserving function in ALS, and preclinical evidence of protective effects of KER-065 in mouse ALS models with improvement in neuromuscular junction structure/function and motor strength. https://www.sec.gov/Archives/edgar/data/1664710/000166471026000003/keros-corporatepresentat.htm
0 · Reply
MacGruber99
MacGruber99 Jan. 9 at 3:19 AM
$KROS tutes be loading up and unloading all the time. float is so small that these events will move the needle.
0 · Reply
sprmn
sprmn Jan. 8 at 9:55 AM
$KROS Max pain price is $20. Buy now and sell at any price beyond $20 if you are holding this short term.
0 · Reply
TheBehavioralTrader
TheBehavioralTrader Jan. 7 at 4:12 PM
$KROS Arbitrage retracement to the company buyback Point good entry area here in my opinion with the correct stop in Target around 21 plus... StockreversalsPremium.com
1 · Reply
okiejames
okiejames Jan. 6 at 4:36 PM
$KROS anyone have a clue whats going on here?
0 · Reply
amessagefromtheodd
amessagefromtheodd Jan. 1 at 9:04 AM
$CADL $IOVA $KROS $SLS $VXRT Happy New Year 🎊 🎈🎆 I have not forsaken you…
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 31 at 6:45 PM
$KROS RSI: 35.34, MACD: 0.6948 Vol: 0.86, MA20: 20.92, MA50: 18.18 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
sprmn
sprmn Dec. 26 at 1:19 PM
$KROS wah $18.87, who is the lucky one?
0 · Reply
amessagefromtheodd
amessagefromtheodd Dec. 24 at 8:30 PM
$SLS I will tell you what $IOVA we must $KROS look after $CADL our own $VXRT The Saga Continues 2026
0 · Reply
sprmn
sprmn Dec. 24 at 12:37 PM
$KROS $KURA $TNXP $XBI where is the crying bear 🐻?
0 · Reply
TheHubSpotter
TheHubSpotter Dec. 24 at 12:15 PM
$KROS Expectations are now anchored to how progress validates the underlying thesis beyond narrative appeal. Long-term optimism depends on disciplined follow-through.
0 · Reply
amessagefromtheodd
amessagefromtheodd Dec. 24 at 2:59 AM
$KROS Interesting 🧐 🤔🤓
0 · Reply
sprmn
sprmn Dec. 23 at 11:40 AM
$KROS $KURA $TNXP $XBI where is the bear? 🐻
1 · Reply
sprmn
sprmn Dec. 23 at 1:37 AM
$XBI where is the bear? 🐻 $KURA $KROS $TNXP
0 · Reply